Elvitegravir: A once daily alternative to raltegravir

The Lancet Infectious Diseases

Volumn 12, Issue 1, 2012, Pages 3-5

  Desimmie, Belete Ayele ^a   Schrijvers, Rik ^a   Debyser, Zeger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COBICISTAT; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; RITONAVIR; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIMIT OF DETECTION; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VIREMIA; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; QUINOLONES;

EID: 84155166847     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70277-8     Document Type: Letter

References (16)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860. and the HIV Outpatient Study Investigators.
2. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services, (accessed Sept 29, 2011). http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
3. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21:2315-2321.
4. Eron JJ, Rockstroh JK, Reynes J, et al, for the QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis; published Sept 19, 2011. DOI:10.1016/S1473-3099(11)70196-7.
5. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006, 43:1-5.
6. Arribas J, Lazzarin A, Raffi F, et al. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276) (accessed Sept 29, 2011). http://pag.aids2010.org/Abstracts.aspx?AID=17600.
7. Eron J, Durant J, Poizot-Martin I, et al. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961) (accessed Sept 29, 2011). http://pag.aids2010.org/Abstracts.aspx?SID=631&AID=12762.
8. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010, 54:254-258.
9. Molina J-M, LaMarca A, Andrade-Villanueva J, et al, for the Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis; published online Oct 19, 2011. DOI:10.1016/S1473-3099(11)70249-3.
10. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999, 13:F17-F21. for the Swiss HIV Cohort Study.
11. Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SAR, Vento S Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006, 6:496-507.
12. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
13. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009, 23:2289-2300.
14. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
15. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011, 203:1204-1214.
16. Study of the safety and efficacy of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 (QUAD) versus Atripla(R) in HIV infected, antiretroviral treatment-naive adults. Aug 23, 2011. (accessed Oct 4, 2011). http://clinicaltrials.gov/ct2/show/NCT00869557?term=NCT00869557&rank=1.